吉利德拟78亿美元收购癌症细胞疗法公司Arcellx

Group 1 - Gilead Sciences announced a proposed acquisition of cancer cell therapy company Arcellx for $7.8 billion [1] - Following the announcement, Arcellx's stock price surged nearly 80% [1] - Gilead's Kite Pharma previously collaborated with Arcellx to develop and market an experimental CAR-T therapy for multiple myeloma [1]